Prevalence of glucose-6-phosphate dehydrogenase deficiency in Southern Province, Zambia by Kurani, Shaheen
Prevalence of glucose-6-phosphate dehydrogenase deficiency in Southern Province, 
















A thesis submitted to Johns Hopkins University in conformity with the 













©2016 Shaheen Kurani 




	   ii 
Abstract  
Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme critical for protecting 
red blood cells from oxidative damage. G6PD deficiency is an X-linked recessive 
disorder caused by mutations in the G6PD gene and affects nearly 400 million people 
worldwide. Among G6PD deficient individuals, it is common to experience premature 
breakdown of red blood cells in the face of oxidative stress, such as administration of the 
antimalarial drug primaquine. Primaquine is effective against the late stage gametocyte of 
Plasmodium falciparum and therefore useful in disrupting transmission. In Macha, a 
town in the Southern Province of Zambia, malaria transmission has declined significantly 
in the past decade. It is hypothesized that a control strategy, such as single-dose 
primaquine treatment, may be an effective tool for potential malaria elimination. 
Unfortunately, there is little information available on local G6PD deficiency prevalence. 
Thus, the primary aim of this project was to determine the prevalence of G6PD 
deficiency in Macha. We focused on the G6PD A- genotype, as it is the most prevalent 
genotype for the deficiency in Africa. In order to determine the prevalence of G6PD 
deficiency, DNA was purified from 56 blood samples collected from Macha in June 
2014. Touchdown polymerase chain reaction (PCR) was done and PCR products were 
digested with restriction enzyme NlaIII to determine which individuals have the G6PD 
A- genotype. Deficient individuals presented a mutation from guanine to adenine at the 
202nd base pair site. The prevalence of G6PD deficiency in Macha was 8.9%. This 
information will help inform the Zambian Ministry of Health’s potential malaria 
elimination strategy involving mass drug administration of primaquine.  
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Background 
Nearly half of the global population is at risk of contracting malaria [1]. Between 
2000 and 2015, the rate of new malaria cases decreased by 37% worldwide [1]. This 
resulted in a 60% reduction in malaria death rates among all age groups, with the 
exception of a 65% decrease seen in children under five years of age [1]. Although there 
seems to be a global decrease in malaria infection, areas such as Sub-Saharan Africa 
continue to carry a disproportionately high global burden of disease. For instance, in 
2015, 89% of malaria cases and 91% of malaria deaths were in this region [1]. The World 
Health Organization (WHO) is attempting to tackle this issue with single-dose 
primaquine administration. Knowledge of the malaria lifecycle is crucial for 
understanding the potential consequences of this approach.  
 
Malaria Life Cycle  
During a blood meal, a malaria-infected female Anopheles mosquito injects 
sporozoites into the human host [2]. These sporozoites infect liver cells and mature into 
schizonts, which go on to rupture and release merozoites [2]. It is important to note that 
in the case of Plasmodium vivax and Plasmodium ovale infections, there is a dormant 
liver stage [2]. In the absence of a dormant liver stage, the merozoites are released and 
begin infecting red blood cells, starting the initial human blood stage [2]. During this 
stage, some merozoites leave the asexual replication cycle and develop into sexual forms 
of the parasite called gametocytes [2]. The gametocytes are ingested by the Anopheles 
mosquito during a blood meal and begin the sporogonic cycle [2]. These gametocytes are 
released into the gut of the mosquito and proceed to mature into gametes [2]. Male and 
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female gametes fuse to form zygotes and develop into moving ookinetes [2]. The 
ookinetes burrow into the mosquito midgut wall and later form oocysts [2]. Each oocyst 
produces thousands of active haploid forms called sporozoites that travel from the body 
cavity of the mosquito to the salivary gland [2].  
 
Primaquine 
The intricacies of the malaria life cycle make it complex and unpredictable. 
Antimalarial drugs target the malaria life cycle at different stages [3]. Some drugs act 
against early gametocytes during the blood stage. However, the antimalarial drug 
primaquine, has potent gametocytocidal activity against mature Plasmodium falciparum 
gametocytes and prevents relapse in cases of Plasmodium vivax infection [3]. Primaquine 
is key to elimination in low transmission areas, as it rapidly reduces the transmission of 
gametocytes between the human host and vector while containing the spread of 
artemisinin resistance [3].  
However, Sub-Saharan Africa’s history of high malaria infection has led to the 
evolution of protective genetic traits against the disease, such as glucose-6-phosophate 
dehydrogenase (G6PD) deficiency [4]. This idea was presented in early studies that 
suggest P. falciparum and P. vivax parasites prefer to invade younger erythrocytes, which 
possess high levels of G6PD enzyme [5]. Consequently, the parasites do not prefer to 
invade older erythrocytes, as enzyme levels are low in these cells [5].  
Ruwende et. al conducted a case-control study on over 2,000 African children to 
test the potential protective effect of G6PD enzyme. They found that children who had 
the African form of G6PD deficiency (G6PD A-) reduced their risk of 
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contracting malaria by 46 to 58% [6]. This study concluded that the selective advantage 
of resistance to malaria was counterbalanced with selective disadvantageous results of 
G6PD deficiency [6].  
The disadvantageous results of G6PD deficiency appear in the face of oxidative 
stress. For instance, treatment with primaquine can cause varying degrees of hemolysis in 
patients with G6PD deficiency. The extent of hemolysis is contingent on the dose and 
duration of primaquine treatment as well as the degree of G6PD deficiency [7]. 
 Some experts in the field argue that a minimal risk is associated with the single-
dose primaquine regimen. Reports show that 14 deaths have been reported in six decades 
of primaquine use in 200 million people [7]. When calculating the prevalence of 
mortality using studies that report a known denominator, the estimated value is 1 in 
621,428 (upper 95% CI: 1 in 407,807) [7]. However, the statistics remain challenged by 
the counterargument that without a practical point-of-care field test, primaquine treatment 
decisions may pose risky hemolytic threats to patients with G6PD deficiency.  
 
Enzyme Structure  
The glucose-6-phosophate dehydrogenase (G6PD) gene is located on the long arm 
of the X chromosome at position 28 [4]. The G6PD monomer consists of 515 amino acids 
and has a molecular weight of approximately 59 kDa [4]. The monomer has two domains 
- the N-terminal domain and beta+α domain [4]. The N-terminal domain contains a β-α-
β nucleotide binding site while the β+α domain consists of an antiparallel nine-stranded 
sheet [4]. As depicted in Figure 1, the dimer interface lies in a barrel arrangement and 
contains a conserved peptide region acting as a substrate binding site [4]. Certain 
4 
resolutions display a coenzyme NADP+ molecule in every subunit of the tetramer close 
to the dimer interface [4]. The enzymatic activity is dependent on the stability of the 
active quaternary structures [4].
 
 
Figure 1. Three-dimensional model of G6PD dimer [4] 
 
Enzyme Function  
Glucose-6-phosphate dehydrogenase catalyzes the first reaction in the pentose 
phosphate pathway, referred to as the committed step [4]. G6PD provides reducing power 
in the form of NADPH by converting glucose-6-phosphate to 6-phosphogluconolactone 
[4]. The conversion permits regeneration of the reduced form of glutathione. Glutathione 
is essential for decreasing the amount of hydrogen peroxide and oxygen radicals in the 
body.  
Glucose-6-phosphate dehydrogenase plays a role in virtually all cell types due to 
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its involvement with the normal processing of carbohydrates [4]. It has a particularly 
important role in red blood cells, protecting them from premature destruction and 
ensuring oxygen transportation throughout the body [4]. The synthesis of NADPH by 
glucose-6-phosphate is crucial for red blood cells as they lack other NADPH-producing 
enzymes and have an increased susceptibility to damage from oxidative stress [4]. 
 
Enzyme Deficiency 
G6PD deficiency is an X-linked recessive disorder that afflicts nearly 400 million 
people worldwide [4]. As a result of the X-linked inheritance pattern, the heterozygous 
genotype, BA-, is only present in females. The biological causes of the deficiency range 
from a reduction in the number of enzyme molecules to structural differences in the 
enzyme [4]. In most cases, G6PD deficiency is due to enzyme instability resulting from 
amino acid substitutions [4].  
With more than 300 variants, G6PD deficiency is prevalent among individuals 
from African, Asian, and Mediterranean descent [8]. G6PD Mediterranean and G6PD A- 
are the two most common variants among humans. G6PD Mediterranean is characterized 
by a substitution of cytosine to thymine at position 188 (SER188PHE) [9]. This genotype 
is prevalent in the Middle East [9].  
  The G6PD A- variant is responsible for the high prevalence of deficiency among 
African populations [8]. This variant differs from the wild-type G6PD B genotype by two 
amino acid substitutions, guanine to adenine at positions 376 (VAL68MET) and 202 
(ASN68ASP) [8]. The first missense mutation encodes the allelic change from G6PD B 
variant to G6PD A variant and the second mutation differentiates the G6PD A- genotype 
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from the G6PD A genotype [8]. The G6PD A genotype has an enzymatic activity of 85% 
whereas the A- genotype has activity levels around 12% [8].  
 The G6PD Mediterranean and G6PD A- genotypes represent opposite ends of the 
severity spectrum for hemolysis associated with primaquine treatment. Adverse reactions 
to primaquine are profound in the G6PD Mediterranean variant and mild in the G6PD A- 
variant. Nevertheless, severe hemolytic reactions can still occur among individuals with 
G6PD A- genotype. Hemolytic risk is difficult to predict given the substantial variability 
in G6PD activity among individuals with the same genotype, and even within the same 
individual over time.  
 
Hemolysis 
There are a few proposed mechanisms for primaquine-induced hemolysis, 
although the process is still not understood in its entirety [3]. One hypothesis suggests 
that the 5-hydroxyprimaquine metabolite is dominated by its oxidized quinoneimine 
species in G6PD deficient red blood cells [3]. The quinoneimine species reacts with the 
heme moiety of hemoglobin and cause its displacement to the lipid bilayer of red blood 
cells [3]. The displacement of the heme moiety results in acute intravascular hemolysis 
[3]. Freely circulating hemoglobin has the potential to cause the most severe clinical 
symptoms, such as renal failure [3].  
Another mechanistic study suggests that glutathione is oxidized to glutathione 
disulfide and lost from the red blood cell [10]. Lastly, some hypotheses point to the 
formation of Heinz bodies as a result of denatured and aggregated hemoglobin on the 
inner surface of the cell membrane [3].  
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Malaria and G6PD Deficiency   
Work done by Howes et al. estimated the frequency of G6PD deficiency across 
malaria endemic countries by creating a prediction map model. Representative 
community surveys of phenotypic G6PD deficiency taken from 1,734 sites were used to 
generate a Bayesian geostatistical model [3]. This model created a G6PD deficiency 
allele frequency map across malaria endemic countries. Unlike existing published maps 
of G6PD deficiency, the maps generated by Howes et al. produced estimates that were 
weighted according to population size. This ensures the estimates were unbiased as 
weighted calculations correct for possible biased distributions. 
Current published maps pose many limitations. For instance, existing maps 
summarize average frequency data to national levels masking sub-national variation [3]. 
Some fail to exclude potentially skewed or unrepresentative survey samples while others 
disregard the prevalence of the deficiency in females, and most maps do not have a 
framework to incorporate spatial heterogeneity into population-affected estimates [3].   
  The results from this study showed that Sub-Saharan Africa had the highest 
continental-level deficiency frequency with 65.9% of the land area having a prevalence 
greater than or equal to 5% [3]. Additionally, 37.5% of the area had a median G6PD 
deficiency prevalence greater than or equal to 10% [3]. Overall, the study calculated a 
G6PD deficiency prevalence of 15-20% in Zambia and 5-15% in Botswana [3]. Howes et 
al. concluded that G6PD deficiency is widespread and spatially heterogeneous across 
most malaria endemic countries. 
A study conducted by the WHO Working Group gave separate but similar 
statistics regarding the global distribution of G6PD deficiency. They noted that 
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approximately 7.5% of the world population carries one or two genes for G6PD 
deficiency [11]. Although the deficiency is an X-linked disorder, females contribute to 
nearly 10% of the deficient population due to the high frequency of the gene and high 
incidence of consanguineous marriages [11]. Ultimately, the WHO Working Group found 
a comparable result to Howes et al. ranking parts of Africa with the highest global 
prevalence of G6PD deficiency at 35%.  
 
Project Aims 
The goal of my project was to inform a malaria elimination strategy proposed by 
the Zambian Ministry of Health (MoH) by determining the prevalence of glucose-6-
phosphate dehydrogenase deficiency in Macha, a town in Southern Province. Macha is in 
the Choma District of Zambia, one of the three project sites for the Southern Africa 
International Centers of Excellence for Malaria Research (ICEMR) team. The number of 
malaria cases in Macha has significantly decreased over the last ten years due to the 
introduction of bed nets and artemisinin combination therapy. However, complete 
malaria elimination can only be achieved by preventing transmission. Thus, the MoH 
hopes to administer the antimalarial drug primaquine, to disrupt the current low levels of 
transmission and eliminate malaria.   
Macha, along with the Southern Province, is populated with individuals from the 
Tonga tribe. Similar to many Zambian tribes, the Tonga practice interbreeding. 
Consequently, the genetic makeup of members from one tribe is generally assumed to be 
homogenous. Under this assumption, the results achieved from our project in Macha may 
be relevant to Southern Province.    
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I hypothesized that the prevalence of G6PD deficiency in Southern Province was 
10-20% - a range that fell in between results from previous studies. Although the 
deficiency is common among certain ethnic groups, there is limited information on the 
distribution of G6PD deficiency in Zambia. By determining deficiency levels, I hope to 




The ICEMR study sites are comprised of three regions with distinct malaria 
transmission and control [12]. As shown in Figure 2, the three sites are Choma and 
Nchelenge Districts in Zambia and Mutasa District in Zimbabwe. Choma District has 
successfully accomplished malaria control while Nchelenge District has not effectively 
controlled malaria transmission [12]. The ineffective control in Nchelenge is apparent by 
the high number of malaria cases each year. Unlike Choma and Nchelenge, Mutasa 
District formerly achieved successful malaria control but is now in a period of resurgence 
[12].  
The focus of this project is on the Choma District in Southern Province, Zambia. 
In 2011, the population of Choma stood at 204,989 [12]. This drought-prone region 
receives the lowest mean annual rainfall in the country and has an unpredictable rainy 
season between November and April [12]. The primary vector in Southern 
Province, Anopheles arabiensis, peaks during the rainy season [12].  
Fortunately, the Southern Province is one of the few regions in Zambia with low 
parasite prevalence [12]. From 2006 to 2010, the prevalence of malaria parasitemia in 
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children under 5 dropped from 13.7% to 5.7% [12]. The decline has been attributed to the 
use of effective artemisinin combination therapy in conjunction with the scale up of 
insecticide treated bed nets [13].  
 
Figure 2. Three Southern Africa ICEMR sites – Choma, Nchelenge, and Mutasa 
Districts [12] 
 
Sample Selection  
The 56 whole blood samples used for my graduate thesis analysis were collected 
from the Choma District in June 2014 as part of an active screening project conducted by 
ICEMR. The active case detection participants were enrolled in prospective longitudinal 
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and cross-sectional surveys of malaria parasitemia in the catchment area of Macha 
Hospital in Southern Province, Zambia [13]. Satellite images were constructed using 
Quickbird to form a sampling frame to randomly select households (Figure 3) [13]. 
However, with low levels of malaria transmission in Macha, the team was unable to 
capture a substantial number of cases through active case detection. Thus, ICEMR 
created the Step-D project to replace active screening.  
 
Figure 3. Map used to randomly select households for active case detection in 
Macha [13] 
 
Step-D and Enhanced Step-D Projects 
The MoH instituted the step-D program to assist with malaria surveillance and 
elimination. The goal of the step-D program was to detect malaria index cases in the 
Choma district with the help of local clinic nurses and staff members. The recruited 
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facilities were provided cell phones and asked to Short Message System (SMS) the 
Macha Research Trust (MRT) when a patient was diagnosed with malaria. After 
receiving notice about a malaria case from a health clinic, the MRT field team would 
determine the location of the index case household and create maps to locate all houses 
within a 140-meter radius from the index case household. The homes within range were 
eligible to participate in the program.  
To assess the adequacy of the 140-meter radius, ICEMR expanded to a 250-meter 
radius around the index case household. The expansion led to the formation of the 
enhanced step-D program. In July 2015, I collected 150 samples from participants 
involved with enhanced step-D. Those samples will be used to conduct a cross sectional 
analyses at a later date.  
 
Location of Houses 
In order to determine the exact location of the index case household and the 
houses within a 250-meter radius, the field team created Geographical Information 
Systems (GIS) maps. An example of a GIS map used by the MRT field team is shown 
below in Figure 4.  
After determining the coordinates of each house, a member from MRT would 
visit the families and provide a light trap to use during the night. During this visit, the 
households were informed about the enhanced step-D program and the role of the light 
trap in informing the study about parasite diversity. The enrolled participants were asked 
to use the light traps until the next day when the field team returned for sample 
collection.  
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Figure 4. GIS map used for enhanced step-D project 
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Enhanced Step-D Fieldwork 
The next day, the field team set up stations central to multiple houses and began 
the sample collection process (Figure 5). One person from the MRT field team was 
responsible for administering a survey while two MRT members were in charge of taking 
blood samples. The survey consisted of questions that assess the use of bed nets, 
antimalarial access and intake, previous malaria infections, and presence or absence of 
clinical malaria symptoms. The blood was obtained through a finger prick and placed in 
capillary tubes as well as on filter paper (Figure 6). The blood sample was also used for a 
rapid diagnostic test (RDT). Individuals who tested positive for malaria by the RDT were 
treated on site with artemisinin combination therapy (Figure 7). Additionally, the field 
team conducted a test to check the participants’ hemoglobin levels.  
     
Figure 5. Central field station set-up 
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Figure 6. Finger prick and capillary tube collection method in the field  













Figure 7. Positive RDT detecting of P. falciparum infection  
 
Purification  
 The protocol from the Qiagen QIAmp DNA blood mini kit was used to purify the 
red blood cell fractions (Figure 8). The cells were lysed to release the DNA, which was 
bound to the spin column then washed to remove residual contaminants. The final elution 
contained purified DNA that was used for the experiment. A complete explanation of the 
protocol can be found in the Appendix.  
	   17 
   
Figure 8. Methods for QIAamp DNA blood mini kit [14] 
 
Polymerase Chain Reaction 
A touchdown polymerase chain reaction (PCR) was conducted to amplify the 
region containing the G6PD gene. In a touchdown PCR, the initial annealing temperature 
is higher than the optimal melting temperature of the primers and is gradually reduced 
over subsequent cycles.  
The methods section presented in the Fanello et al. paper was initially followed to 
perform the PCR. However, when using the study’s protocol, no signals appeared in the 
gel images. This led to three months of troubleshooting. Multiple troubleshooting 
	   18 
strategies were attempted, such as making new dNTP, diluting and concentrating the 
DNA by 10x, and changing the gel concentration (Figure 9). A strong signal was finally 
observed when red blood cell fractions were used in place of the dry blood spots and a 
Phusion High Fidelity DNA-Polymerase replaced the Taq polymerase. A stronger signal 
was achieved due to larger sample quantity and stronger binding of the polymerase. The 
Phusion High Fidelity polymerase was less error-prone than the Taq polymerase allowing 
for more precise binding to the DNA in our samples.  
  
A)     B)     C) 
 
Figure 9. Troubleshooting results a) new dNTP b) DNA dilution 10x c) Phusion 
polymerase indicating band at 461 bp 
 
Once the samples were purified using the QIAamp kit, a master mix was made 
using 5μL of high fidelity buffer, 2μL of 5μM dNTP, 1.25μL of forward and reverse 
primers, 0.75μL of DMSO, 0.25μL of Phusion polymerase, and 11.5μL of purified H2O. 
The amounts listed are for one sample. The master mix was then vortexed, centrifuged, 
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and added to centrifuge tubes. 22μL of master mix was added to 3μL of sample template. 
This tubes was centrifuged at 4° C then placed in the PCR machine at the conditions 
listed in Table 1.   
 
Table 1. PCR conditions 
Initial Denaturation 98° C 30 seconds 
25-35 Cycles 98° C 5-10 seconds 
 45-69° C 10-30 seconds 
 72° C 15-30 seconds 
Final Extension  72° C 5-10 minutes 
Hold  4° C ∞ 
 
Gel and Imaging 
In order to visualize the PCR product, a 2% agarose gel was made using 1.0 gram 
of agarose gel powder and 50ml of 1x TAE buffer. This mixture was weighed then 
microwaved until all of the powder was dissolved. To compensate for evaporated liquid, 
the appropriate amount of water was added to achieve the initial weight. Finally, 2.5μL of 
ethidium bromide was added to the liquid gel, which was then mixed and poured into the 
set tray to solidify.  
To load the gel, 1μL of loading dye, 5μL of sample, and 1.4μL of 1,000kb DNA 
ladder were used. The gel was run at 100 watts on the DC setting for 25 minutes. Once 
the gel was finished running, it was imaged to confirm proper amplification, indicated by 
a band at 461bp.  
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Restriction Enzyme Digest 
The next step was to conduct an NlaIII restriction enzyme digest on the PCR 
product. This digest was performed to observe the appropriate cuts for G6PD A- 
genotype. The NlaIII enzyme makes a cut at the 202nd base pair site in G6PD deficient 
individuals indicating a substitution from guanine to adenine.  
Similar to the PCR, a master mix was made for the restriction enzyme digest. The 
following mixture is for one sample: 3μL of 10x NlaIII buffer, 0.6μL of NlaIII enzyme, 
and 6.4μL of purified H2O. The master mix was vortexed and centrifuged. 10μL of 
sample was added to 20μL of the PCR product and placed into the PCR machine. The 
digest conditions are listed in Table 2. 
 










A metadata spreadsheet was used to retrieve information on each of the study 
participants. The metadata provided date of birth, age, gender, date of sample collection, 
country, district location, GPS coordinates, health status, and parasite detection/load 
(Table 1). The 56 samples analyzed in this study were made up of 54% males (n=30) and 
37° C 60 minutes 
65° C 20 minutes 
4° C ∞ 
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46% females (n=26). The median age among men was 18 years and the interquartile 
range was 36.8 years. Similarly, the median age among women was 22 years and the 
interquartile range was 35.5 years.  
The 32-year-old male who tested positive for G6PD deficiency was the only 
individual who did not fall within the normal hemoglobin rage for his age. Normal 
hemoglobin range for adult males is between 14-18 g/dL [15] [16].  
 
Table 3: Demographics for G6PD deficient individuals in Choma District 
Age Gender GPS (Longitude, 
Latitude) 
Hemoglobin Level (g/dL) 
5 Male -16.3859419,  
26.88840474 
13.5 


















Figure 10 shows the expected results associated with each genotype, bearing in 
mind the heterozygous form is only possible in females. Distinct cuts and band sizes 
distinguished the respective genotypes. For instance, a sample that was not digested 
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would present a band at 461bp. This is the same band length that was observed from the 
PCR if proper amplification was achieved. An individual with G6PD B genotype would 
show band lengths of 296bp and 165bp. These bands indicate the wild type genotype and 
normal enzymatic activity. An A- genotype expression would have bands at 173bp and 
123bp. And not surprisingly, a heterozygous woman with a BA- genotype would present 
a combination of bands from the B and A- genotypes. She would display bands at 296bp, 
173bp, and 123bp.  
 
  
Figure 10. Expected restriction enzyme digest results [8] 
 
Results 
Ultimately, we determined a G6PD deficiency prevalence of 8.9% in Choma. Five 
out of the 56 samples from June 2014 showed positive digest results for G6PD A- 
genotype (Figures 11 & 12). We were 95% confident that the true value of G6PD 
deficiency in Macha was between 1.5 and 16.4%.  
The 5 individuals who presented bands for the A- genotype were all male 
participants (Figure 13). Household clustering was evident among deficient individuals.  
Three of the individuals who were positive for G6PD deficiency lived in the same 
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household; their ages were 5, 9, and 32 years. The two other participants, aged 9 and 14 
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Figure 12. Digest results indicating G6PD B genotype for all samples 
 
A)             B) 
 
Figure 13. a) PCR product for 3 male samples b) digest results showing G6PD A- 
genotype for third sample 
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Discussion  
Conclusions 
This study aimed to determine the prevalence of G6PD deficiency in Macha, 
Zambia, a town in Southern Province. After purifying the samples, performing PCR, and 
conducting a restriction enzyme digest, we concluded a prevalence of 8.9% for the G6PD 
A- genotype. The 95% confidence interval was 8.9% +/- 7.5%.  
 
Limitations 
As mentioned previously, the small sample size of this project may affect the 
generalizability of the obtained results. However, we can assume a similar genetic make 
up for most individuals living in Southern Province, as they are part of the Tonga tribe. 
Historically, the Tonga tribe has maintained a reputation for interbreeding allowing us to 
make this assumption.  
Another limitation may be the appearance of signal in the negative control on the 
PCR gel image. Signal in the water control is a sign of potential contamination. We faced 
this problem towards the end of our project. However, we confirmed that this issue did 
not affect our results; the bands produced from the samples showed a much stronger 
signal and were eventually digested unlike the band in the negative control.  
Additionally, the use of water as the negative control may not suffice as the sole 
control. Thus, it would be beneficial to incorporate the use of a target gene apart from the 
G6PD gene to confirm that we are amplifying the correct gene region. It would also be 
useful to include a positive control, such as a sample that has been amplified previously. 
The positive control plays an important role in the event bands are not seen in the gel 




Due to the small sample size used for this study, I will analyze the 150 samples 
from July 2015 in the upcoming months. This will hopefully increase the validity of our 
results. I am hoping to finish the 2015 samples by April in an effort to publish my 
results.  
In future studies, recruitment should be done using individuals from other districts 
within Southern Province. Moving outside of the Choma District will provide a more 
diverse sample population, thereby increasing generalizability of the results.  
In addition, conducting future analyses will inform existing literature on G6PD 
deficiency. There are theories in the field about possible protective effects of G6PD 
deficiency against malaria [4]. Additional work could potentially uncover a possible 
correlation between high malaria transmission and high prevalence of G6PD deficiency.  
Because G6PD deficiency can result from mutations at multiple base pair sites, it 
is important for future studies to perform a biochemical analysis in addition to the PCR 
and restriction enzyme digest. This provides an assessment of full enzymatic activity 
rather than limiting the study to the 202nd base pair site. Fortunately our methods sufficed 
for this project because the study population was mainly at risk for the A- genotype. 
 
Significance in the Field 
There is limited published literature on G6PD deficiency in Sub-Saharan Africa. 
In fact, many studies fall short of reliable methods to determine deficiency levels. As 
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mentioned previously, predictive map models leave out critical information or include 
skewed data when producing estimates. In addition, it is very difficult to distinguish 
heterozygous deficient patients from healthy individuals without reliable methods for 
diagnosis. Because our methods involved laboratory techniques, we can achieve 
conclusive results and detect changes at a genomic level. I hope the results from my 
graduate thesis project will play a significant role in informing malaria control policy and 
other large-scale initiatives taking place in Sub-Saharan Africa.   
The National Malaria Control in Zambia has been informed of my results and is in 
the process of reviewing their primaquine administration strategy. A final decision has 
not yet been reached but will hopefully be made within the next year. Without a strategy 
to complement the current malaria control techniques in Macha, the area is at risk for a 
resurgence of high malaria infection. Thus, the MoH needs to take action now by creating 
a safe and practical method to eliminate malaria while transmission is low.   
My personal recommendation to the Zambian MoH is to assess the ethical 
dilemma at hand before implementing policy-level changes. One suggestion that may aid 
in the decision-making process is conducting a population screening of newborn babies 
for G6PD deficiency. This would be particularly important among males but also in areas 
with a high or unknown prevalence. Given the complexity of both malaria and G6PD 
deficiency, there may not be one single solution that will ensure safe and effective 
primaquine treatment. Based off the data from this project, I am inclined to support 
single-dose primaquine administration in Macha. I hope experts can continue making 
progress on the malaria vaccine and RDTs for G6PD deficiency to help the Zambian 
MoH create a multi-pronged solution in a timely manner.  
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Appendix  
Purification protocol  
Red blood cell fractions were purified using a Qiagen QIAamp DNA blood mini 
kit (Figure 8). To begin the process, the blood samples were brought to room temperature 
and the hot water bath was heated to 56° C. The protease and buffers were prepped with 
ethanol and the buffers were brought to room temperature. The following procedure was 
employed for the purification process: 
1.  Pipet 20μL of Qiagen protease into a 1.5ml tube. 
2.  Add 200μL of sample to this tube. 130μL of PBS was added to each sample in order to 
attain a total volume of 200μL. 
3.  Add 200μL of buffer AL to the sample then pulse vortex for 15 seconds. 
4.  Incubate samples at 56° C for 10 minutes. 
5.  Centrifuge the 1.5ml tube briefly and add 200μL of ethanol (96-100%) to sample. 
6.  Pulse vortex for 15 seconds then centrifuge briefly. This ensures optimal binding of 
the DNA to the QIAamp membrane before the sample is loaded into a spin column.  
7.  Apply the mixture from above to a mini spin column without wetting the rim. Close 
the cap and centrifuge at 8,000 rpm for 1 minute. During this step, DNA is adsorbed 
onto the QIAamp silica membrane. 
8.  Place the spin column in a clean 2ml collection tube and discard the tube containing 
the filtrate. 
9.  Open the spin column and add 500μL buffer AW1. Centrifuge at 8,000 rpm for 1 
minute. This is the first of two wash steps that allows complete removal of residual 
contaminants without affecting DNA binding.  
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10. Place the spin column in a clean 2ml collection tube and discard the tube containing 
the filtrate.  
11. Add 500 μL Buffer AW2 to the spin column without wetting the rim and centrifuge at 
full speed (14,000 rpm) for 3 minutes.  
12.  Discard the tube containing filtrate and place in new spin column. Centrifuge at 
14,000 rpm for 1 minute.  
13.  Place the spin column in a clean 1.5ml microtube and discard the tube containing the 
filtrate. Open the column and add 200μL of buffer AE. Incubate at room temperature 
for 1 minute then centrifuge at 8,000 rpm for 1 minute.  
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